NAD+ for Longevity: Protocols, Precursors & What the Data Shows
Nicotinamide adenine dinucleotide is a coenzyme required by every cell for energy metabolism and by the sirtuin and PARP enzyme families for DNA repair and metabolic regulation. Tissue NAD+ falls substantially across the lifespan. That much is solid. What follows from it is where the field gets loose.
Why NAD+ Declines and Why It Matters
NAD+ levels in muscle, liver, brain and skin decline with age, driven by both reduced synthesis and increased consumption — notably by CD38, an NADase whose expression rises with inflammatory aging, and by PARP enzymes responding to accumulated DNA damage. Because sirtuins are NAD+-dependent, falling NAD+ reduces the activity of a regulatory system tied to mitochondrial biogenesis, DNA repair and metabolic flexibility.
The Precursor Options
NAD+ itself is a large, charged molecule with poor oral bioavailability, so most strategies deliver precursors that cells convert intracellularly. The three commonly used routes differ substantially in evidence and cost.
What Human Trials Actually Found
Trials of NR and NMN consistently show one thing: they raise blood NAD+ levels, often substantially, and they are well tolerated over the durations studied. Downstream clinical outcomes are far less consistent. Studies have reported modest improvements in some measures of muscle function, insulin sensitivity or aerobic capacity in specific populations, alongside multiple well-conducted trials showing no significant benefit on the primary endpoint. No trial has tested a human aging or lifespan outcome, because no such trial is feasible at current durations.
The biomarker gap
Raising a biomarker is not the same as improving a health outcome. NAD+ restoration is currently a well-supported biomarker intervention with an unresolved outcome question. Anyone telling you otherwise is selling something.
Where signals are strongest
The most encouraging human signals appear in older adults with low baseline function and in metabolic contexts rather than in healthy young subjects — consistent with the idea that repletion helps most where depletion is real.
Protocols People Use
Commonly reported regimens are 250–1,000 mg per day of NR or NMN taken in the morning, or injectable NAD+ at 50–100 mg subcutaneously several times weekly, often cycled. IV protocols in clinics typically run 250–750 mg per session over several hours because faster infusion causes marked discomfort. These are observed practices, not evidence-based recommendations, and injectable routes have no controlled human dosing data at all.
Safety and Open Questions
Oral precursors have shown good short-term tolerability across trials up to about a year. The unresolved questions are long-term: whether sustained elevation affects methyl group demand, and whether NAD+ elevation could support proliferation of existing malignant cells — a theoretical concern raised in the literature and not resolved by any trial. Injectable NAD+ adds sterility and product-quality risk that oral capsules do not carry.
Product Quality: The Bigger Practical Problem
Independent testing of NMN and NR products has repeatedly found label claims that do not match contents, including products containing a fraction of stated dose. Injectable NAD+ sold outside a compounding pharmacy carries the further risks of endotoxin contamination and incorrect concentration. If you are spending meaningfully on this category, testing what you bought is a rational use of a small fraction of that spend.
Frequently Asked Questions
Does NAD+ supplementation extend lifespan in humans?
No human trial has tested lifespan. Trials show NAD+ levels rise reliably; clinical outcome benefits are inconsistent and modest where present.
Is NMN better than NR?
Both raise NAD+ in human trials. There is no head-to-head evidence establishing clinical superiority of either.
Are NAD+ injections worth it over oral precursors?
Injectables bypass first-pass metabolism, but no controlled trial has compared them to oral precursors on any outcome, and they add sterility and product-quality risk.
References
Report a Safety Issue
If you've experienced health issues after using this peptide, please report it. Your report helps us track safety issues and protect other users.
Report Adverse Event